Compare BG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BG | GH |
|---|---|---|
| Founded | 1818 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8B | 22.9B |
| IPO Year | 2023 | 2018 |
| Metric | BG | GH |
|---|---|---|
| Price | $103.81 | $167.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 26 |
| Target Price | $141.78 | ★ $200.24 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $70,329,000,000.00 | $982,021,000.00 |
| Revenue This Year | $30.44 | $38.23 |
| Revenue Next Year | $2.72 | $35.14 |
| P/E Ratio | $308.06 | ★ N/A |
| Revenue Growth | 32.43 | ★ 32.88 |
| 52 Week Low | $79.12 | $61.00 |
| 52 Week High | $134.87 | $191.05 |
| Indicator | BG | GH |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 46.52 |
| Support Level | N/A | $153.88 |
| Resistance Level | $126.62 | $173.94 |
| Average True Range (ATR) | 2.82 | 7.36 |
| MACD | -0.57 | -1.75 |
| Stochastic Oscillator | 4.89 | 22.06 |
Bunge Global SA is an agribusiness solutions company, connecting farmers to consumers and delivering essential food, feed and fuel to the globe. The company segments include Soybean Processing and Refining; Softseed Processing and Refining; Other Oilseeds Processing and Refining; Grain Merchandising and Milling; and Corporate and Other. It generates maximum revenue from the Soybean Processing and Refining segment, which includes integrated business principally involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution. Geographically, the company operates in United States, Switzerland, Netherlands, and Rest of the World.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.